NEWS: Our Blog


Recent Posts

Customer Survey Results for 2016

Dec 14, 2016 3:20:00 AM / by adminweb_1 posted in Pharmaceuticals


In 2016, Alliance Pharma conducted a Customer Survey to measure satisfaction of our bioanalytical, biopharmaceutical, and drug metabolism services to our clients. Our goal was to assess how we were performing in relation to our business philosophy. Since we measure our success based on the success of our clients, it is important that we understand the areas of our business that are working and the areas that need improvement.

Overall, 100% of clients who responded to our survey gave Alliance Pharma a rating of SATISFIED or higher in regards to questions about services, personnel, performance, support, management, and costs. In fact, 75% of clients stated that they are VERY SATISFIED with Alliance Pharma.

customer survey results very satisfied

The Customer Survey went out to Scientific Directors, Senior Research Directors, Assistant Scientists, Senior Managers, and Professors. When these clients were asked, “How satisfied are you with the performance of our technicians?” 70% replied that they are VERY SATISFIED. In addition, 65% of our clients responded that they are VERY SATISFIED with our management’s commitment to assist.

Customer Survey Data

We also used the survey to understand why our clients are choosing to partner with us. We know that there are many CROs in the marketplace, so we value each and every client. The replies showed that our network is strong and that referrals are the number one factor for our clients choosing to partner with us. The survey also revealed that our clients are choosing us for other reasons, as follows:

  • Timing
  • Cost
  • Quality
  • Location
  • Assay Capability

Customer Focused Improvements

Based on the results of the survey, we plan to update our website design and functionality. We will also create new company literature to describe the full extent of our services, especially those that we have added this year, such as the Laboratory Animal Facility and Large Molecule Bioanalysis.

Alliance Pharma would like to thank all of our customers for their time in completing the survey to help us understand how we can better serve all your needs! We are committed to delivering the highest quality services at a competitive price, and thus build a lasting partnership. Thank you for your continued patronage.

Read More

Conference for Pharmaceutical Scientists AAPS2016

Dec 7, 2016 4:47:00 AM / by adminweb_1 posted in Conferences


On November 13, our team of top scientists traveled to Denver, Colorado for the 2016 AAPS Annual Conference for pharmaceutical scientists. The conference was kicked off with a keynote address from Daniel Fletcher, PhD who discussed novel technology, new delivery modalities, accelerated drug development, and precision medicine. Our booth, which was serendipitously situated next to the Rest and Relaxation Lounge, welcomed a host of pharmaceutical professionals, academic leaders, and job-seekers. Visitors received an Alliance Pharma lunchbox or a handy letter opener.

conference for pharmaceutical scientists swag

Many connections were made at the various networking events like the Welcome-Reception, the American Chinese Pharmaceutical Association Meeting, and the 80’s Party hosted by Core RX and Mutchler Inc. Presenters and attendees at the conference included Teva, BASF, Agilent, Triangle Research Labs, Science Exchange, MedPace, and Pfizer, to name a few. Many members of the FDA were also onsite.

Researchers seeking a CRO (contract research organization) find value in the conference because they can make a trusted in-person connection and quickly discern the qualities of a specific CRO. For example, the ideal CRO offers quick-turn around, high-quality data, and competitive pricing. The conference was also an opportunity to share updates on our company. This year, Alliance Pharma had added a Vivarium for animal research studies and a new lab for Large Molecule Bioanalysis.

Tweets from #AAPS2016

Dr. Meng Feng presented a poster on microsampling titled Mouse Pharmacokinetic Study of Ceftriaxone Using MitraTM Microsampling Devices. (View the full details here.) In his work with a group of Alliance colleagues, Dr. Feng concluded that MitraTM microsampling devices provide a methodology that can be used for serial blood sampling in drug discovery mouse studies, and which could reduce costs, improve animal welfare, and save precious test articles.

Dr. Yong Lin presented a poster on Adaptation and Validation of a Multiplex Assay Kit for the Quantitative Analysis of Aβ38, Aβ40, and Aβ42 Peptides in Cynomolgus Monkey Plasma at AAPS. (View the original poster here.)

2017 Conference for Pharmaceutical Scientists

If you are seeking another conference for pharmaceutical scientists, consider joining us in 2017 at one of our upcoming events. View the full conference schedule here.

Read More

Dr. Weiqing Chen to Head Alliance Pharma’s Drug Metabolism Department

Sep 30, 2016 5:01:00 AM / by adminweb_1 posted in Uncategorized


drug metabolism scientist, DMPK, weiqing chen, alliance pharmaAlliance Pharma is pleased to announce the appointment of Weiqing Chen, PhD, to the position of Director, Drug Metabolism. Dr. Chen brings more than 14 years of research and industry experience in drug discovery and development. He established the DMPK (drug metabolism and pharmacokinetic) service capability at a leading CRO in China. While there, he developed stable business relationships with more than 100 clients in US, Europe, Japan, and China. He led the DMPK effort in numerous integrated drug discovery and development programs. He also made significant contributions in designing and managing preclinical DMPK studies for regulatory filings in the US and China. His most recent publication was “Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation,” published in the Drug Metabolism and Disposition Journal.

We are thrilled to welcome Dr. Chen for his expertise in designing and conducting ADME studies, as well as LC-MS/MS method development and sample analysis. Frank Li, PhD, Co-founder and President of Alliance Pharma, acknowledged, “With Weiqing’s many years of DMPK experience, knowledge, and strong leadership, Alliance Pharma will continue to provide clients with the highest level of service.” Dr. Chen is excited to share our passion for providing high-quality DMPK services to the growing needs and expectations of our international clients.

Read More

Gordon Research Conference on Drug Metabolism 2016

Jul 20, 2016 5:05:00 AM / by adminweb_1 posted in Conferences


Alliance Pharma attended the Gordon Research Conference on Drug Metabolism on July 10–15, 2016. The conference took place at the Holderness School in Holderness, NH. Alliance Pharma was one of the sponsors of the conference. The conference brings together industry, academic, and regulatory scientists with interests in Drug Metabolism. The goal of the conference was to address the revolutionary changes happening in the discovery of highly selective medicines and therapeutic regimens for patients with inherited and acquired diseases.

Gordon research conference on drug metabolism

Pictured: conference attendees including Dr. Michael Liu, Dr. Zhiyang Zhao , and Dr. Karsten Holm from Alliance Pharma.

Read More

AAPS Distinguished Service Award to Masood Khan

May 17, 2016 5:11:00 AM / by adminweb_1 posted in Leadership


masood khan AAPS awardAlliance Pharma’s Vice President of Biopharma Services, Masood Khan, Ph.D., was honored with the BIOTEC Section Distinguished Service Award at the 2016 National Biotechnology Conference of the American Association of Pharmaceutical Scientists (AAPS). The AAPS Distinguished Service Award recognizes exemplary service as reflected in significant and extensive contributions that have materially influenced the advancement of the pharmaceutical sciences and the AAPS.

To date, Dr. Khan has over 120 publications and presentations, including several white papers related to issues in bioanalysis that focus on new technologies and biomarkers. One of these white papers titled, “Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development,” which was published in the journal of Bioanalysis (January 2015), offered a systematic approach to the assessment, method adaptation, and validation of commercial immunoassay kits for the quantification of biomarkers in drug development. Dr. Khan is also editor of a book titled, Ligand-Binding Assays: Development, Validation, and Implementation in the Drug Development Arena (2009)—a consolidated and comprehensive reference that is still used extensively in the pharmaceutical industry.

Dr. Khan has been an extraordinary volunteer, actively involved in AAPS over the past two decades, serving on a variety of committees, as well as organizing scientific short courses, roundtables, and symposia. Most notable is a roundtable that he organized at the AAPS 1998 Annual Meeting in San Francisco on the challenges of immunoassay validation and implementation in regulatory environment. This led to the publication of the first white paper on the industry perspectives on ligand-binding assay validation in 2000 and subsequently to the formation of the Ligand-Binding Assay Bioanalytical Focus Group (LBABFG), where he has actively served on the Steering Committee for over 8 years. He is currently acting as the Liaison of the BIOTEC Section Focus Groups.

Read More

Zhiyang Zhao, Chief Scientific Officer

Sep 15, 2015 5:26:00 AM / by adminweb_1 posted in Leadership

1 Comment

Alliance Pharma is pleased to announce that Zhiyang Zhao, PhD, has joined its leadership team as Chief Scientific Officer (CSO).

zhiyang zhao, chief scientific officer, alliance pharma

Dr. Zhao brings to Alliance Pharma over 20 years of pharmaceutical industry experience with special focus on metabolic and pharmacokinetic properties of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Most recently, Dr. Zhao served as Amgen’s Site Director for Preclinical Studies at Cambridge, Massachusetts, for over 11 years. He previously served as a Director at GlaxoSmithKline and as an Investigator at Pfizer. His extensive experience spans the entire drug discovery and development process (discovery, development, and in-/out-licensing) in oncology, metabolic, antiviral, CNS, and inflammatory diseases.

Dr. Zhao’s contributions and accomplishments of integrating in vitro and in vivo ADMET (absorption, distribution, metabolism, excretion, and toxicity) information to optimize drug candidate properties are documented in over 50 peer-reviewed scientific publications and patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology. He currently also holds an appointment as Adjunct Professor at the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill, North Carolina, and serves as the Editor-In-Chief for Drug Metabolism Letters.

“We are thrilled to have Dr. Zhao on our scientific leadership team; he will further strengthen and broaden our scientific excellence in the services that we provide,” said Frank Li, PhD, Co founder and President of Alliance Pharma. “In his role as CSO, Dr. Zhao, will provide scientific, intellectual, and managerial leadership as well as explore scientific and business opportunities beyond Alliance Pharma’s current scope of business.”

Dr. Zhao expressed his excitement in joining the diverse team at Alliance Pharma, stating, “I look forward to working with the talented team at Alliance Pharma as we explore new business opportunities and expand our scientific and technical capabilities to better serve our clients. Having spent more than two decades in various leadership roles in pharmaceutical companies, I fully understand our clients’ challenges and needs.”

Read More

Project Bread Walk for Hunger 2015

May 6, 2015 5:29:00 AM / by adminweb_1 posted in Donations


On Sunday, May 3, 2015, Alliance Pharma participated along with 40,000 people in Boston’s 47th annual “Walk for Hunger.” The 20-mile route wound around Boston and surrounding communities and raised money to create sustainable solutions for hunger in Massachusetts. This year’s walk raised more than $3 million. Alliance Pharma raised $500 and walked the whole 20 miles to support this great cause. Thank you for your donations and support!

walk for hunger, boston

Read More

Fastest Growing Private Companies Recognition

Nov 30, 2014 5:33:00 AM / by adminweb_1 posted in Feng Li


In 2014, Alliance Pharma was recognized as one of the 100 fastest growing private companies in Philadelphia by the Philadelphia Business Journal. 
Alliance Pharma Philadelphia 100 fastest growing private companies

Read More

Meso Scale Discovery® (MSD) V-PLEX Aβ Peptide Panel

Nov 25, 2013 5:38:00 AM / by adminweb_1 posted in Immunoassay


Alliance Pharma has successfully completed testing and validation of the Meso Scale Discovery® (MSD) Human V-PLEX Aβ Peptide Panel 1 Assay (6E10).  With the completion of this validation, Alliance Pharma becomes the first global CRO to validate the Aβ V-PLEX Panel 1, and greatly expands its analytical capabilities in Alzheimer’s and Neurodegenerative Diseases.

The MSD Aβ V-PLEX Panel 1 (6E10) is a multiplexed sandwich immunoassay which measures three amyloid peptides of significance to Alzheimer’s disease: Aβ42, Aβ40, and Aβ38.  MSD neurodegenerative disease assays provide a sensitive method for measuring the levels of peptide and protein targets within a single, small-volume sample.  V-PLEX immunoassays are developed under rigorous design control and are fully validated according to “Fit for Purpose” principles.

Sensitive biomarker assays are proving crucial to the design and execution of clinical trials that target the earliest stages of Alzheimer’s disease.  The Aβ Peptide Panel 1 (6E10) kit is validated for human CSF and thus is ideally suited for this purpose.

“The addition of the Meso Scale Discovery® MSD Aβ V-PLEX immunoassay to our service portfolio will further help our sponsors in the development of drugs to treat neurodegenerative diseases” said Dr. Feng Li, President of Alliance Pharma.

Read More

Philadelphia Business Journal- Success Stories

Sep 30, 2013 5:43:00 AM / by adminweb_1 posted in Feng Li, CEO, Philadelphia, minority owned business, success



Years in business: 6

What made you start your business?
I got the idea a long time ago. I worked in same industry as I am now. I got intensive training. I appreciate the experience I got from that company. I was working very hard at learning and thinking about starting the business. By 2006, I began doing research on how to prepare for new business.

What did you do to survive the recession?
Alliance Pharmaceuticals was started in May 2008. We spent almost $1 million, however, only made about $28,000 with three key employees that year. We stuck with our initial business plan, focused on our expertise area, spent time to build up necessary functionalities and prepare for any potential business opportunities. All three employees deferred their pay for a year to ensure the business operation.

What has made your business successful?
We firmly adhere with our business philosophy including professional ethics, scientific excellence, regulatory compliance to win clients trust. We also have maximum business flexibility to understand our clients needs to meet and exceed their expectations.

What is the hardest part of your job?
The regulatory compliance to ensure the data quality and integrity and hiring the right employees.

What advice would you give someone starting their career or looking to start a business?
Have a dream, make a plan, prepare and execute it. You also must be confident enough to be persistent.

Would your advice be any different if you were addressing a minority?
There is no difference. The principle would be the same.


Excerpt from Philadelphia Business Journal

Read More